Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI : vimarsana.com

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly afterVANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 -- Absci Corporation , a data-first generative AI drug creation...

Related Keywords

Switzerland , Vancouver , British Columbia , Canada , New York , United States , Sean Mcclain , Alex Khan , Innovation Center , Youtube , Securities Exchange , Exchange Commission , Absci Corporation Nasdaq , Ai Research Lab , Linkedin , Drug Creation , New York City , Securities Act , Securities Exchange Act , Markets ,